文献速递肿瘤 PET/CT骨显像与常规 SPECT

18F-氟胆碱PET/CT补充动态对比增强MRI在前列腺癌根治术后疑似复发患者综合诊断中的作用

18F-Fluorocholine PET/CT Complementing the Role of Dynamic Contrast-Enhanced MRI for Providing Comprehensive Diagnostic Workup in Prostate Cancer Patients With Suspected Relapse Following Radical Prostatectomy.
PubMed 文献 · Clin Nucl Med · 2017-01-01

本研究比较了18F-氟胆碱(FCH)PET/CT与盆腔动态对比增强MRI(DCE-MRI)在根治性前列腺切除术后生化复发(BCR)患者再分期中的诊断效能。20例患者均接受全身FCH PET/CT和盆腔DCE-MRI,以组织病理学为标准,两种方法在前列腺床复发、盆腔淋巴结转移和盆腔骨转移的检出率相近,FCH PET/CT还有助于发现未知远处转移。作者认为两者联合可提供互补且全面的诊断评估。

要点

  • FCH PET/CT与DCE-MRI对前列腺癌复发的敏感性、特异性及预测值相近。
  • FCH PET/CT在部分患者中可发现未知的远处转移。
  • 全身FCH PET/CT联合盆腔DCE-MRI可提供互补的综合诊断评估。

核心结论

  • 全身FCH PET/CT与盆腔DCE-MRI联合可提供互补且全面的诊断评估,有助于改善根治性前列腺切除术后生化复发前列腺癌患者的管理。

研究设计与样本

  • 本研究纳入20例根治性前列腺切除术后出现生化复发的前列腺癌患者,均接受全身18F-氟胆碱PET/CT和盆腔动态对比增强MRI,以组织病理学分析为诊断标准。

主要发现

  • MRI检出前列腺床原发肿瘤复发6例(6/20,30.0%)、盆腔淋巴结转移4例(4/20,20.0%)、盆腔骨转移2例(2/20,10.0%);FCH PET/CT在相应部位分别检出7例(7/20,35.0%)、9例(9/20,45.0%)和2例(2/20,10.0%)。
  • FCH PET/CT与MRI在前列腺癌表征的敏感性、特异性、阳性预测值和阴性预测值方面结果相近。
  • 全身FCH PET/CT在相当比例的患者中有助于识别未知的远处转移。
  • 患者初始平均Gleason评分为6.3±1.53(范围4-9),复发时平均前列腺特异性抗原水平为1.9±2.87 ng/mL(范围0.24-13.2 ng/mL)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to compare the diagnostic performance of F-fluorocholine (FCH) PET/CT and dynamic contrast-enhanced MRI (DCE-MRI) of pelvis in restaging prostate cancer (PC) patients with biochemical recurrence (BCR) following radical prostatectomy (RP). METHODS: Twenty PC patients who had undergone RP and had BCR were recruited in this study. All the patients underwent whole-body FCH PET/CT and DCE-MRI of the pelvis. An overall pattern of recurrent disease was analyzed, and diagnostic accuracy for the detection of pelvic disease recurrence by the 2 modalities was evaluated by taking histopathologic analysis as the criterion standard. The whole-body FCH PET/CT images were also analyzed separately for the presence of any extra lesion(s). RESULTS: The initial mean Gleason score was 6.3 ± 1.53 (range, 4-9). The mean prostate-specific antigen levels at the time of relapse were 1.9 ± 2.87 ng/mL (range, 0.24-13.2 ng/mL). MRI findings were positive for primary tumor recurrence in the prostate bed in 6 patients (6/20 [30.0%]), pelvic lymph node metastases in 4 patients (4/20 [20.0%]), and for pelvic skeletal metastases in 2 patients (2/20 [10.0%]), respectively. On the other hand, FCH PET/CT results were positive in the corresponding sites in 7 (7/20 [35.0%]), 9 (9/20 [45.0%]), and 2 patients (2/20 [10.0%]), respectively. F-fluorocholine PET/CT and MRI showed comparable results in terms of sensitivity, specificity, and positive and negative predictive values for PC characterization. The whole-body FCH PET/CT was found to be useful in identifying unknown distant metastases in a significant proportion of patients. CONCLUSIONS: The correlative whole-body FCH PET/CT and pelvic DCE-MRI offer a complementary and comprehensive diagnostic workup for better management of PC patients with BCR following RP.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Vadi SK, Singh B, Basher RK, et al. 18F-Fluorocholine PET/CT Complementing the Role of Dynamic Contrast-Enhanced MRI for Providing Comprehensive Diagnostic Workup in Prostate Cancer Patients With Suspected Relapse Following Radical Prostatectomy. Clin Nucl Med. 2017. PMID: 28525448. doi:10.1097/RLU.0000000000001689

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。